Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPO: Daily Temozolomide for Elderly Glioblastoma
NCT07476794Phase 2Recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Nov 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of temozolomide in glioblastoma (GBM), sponsored by Sunnybrook Health Sciences Centre. Started Nov 2025; status: recruiting.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07476794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07476794.